argenx beats on strong sales, buys Forte to expand pipeline
Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.
This is the main new financial result that directly shows the company's strong performance and supports the stock.
VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.
This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.
Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.
This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.